根据经营发展需要，公司拟在当前持有控股子公司上海昊为泰生物科技有限公司 （以下简称"昊为泰"）51%股权的基础上，以 1,788.50 万元的对价收购少数股东上海 天昊生物科技有限公司持有的昊为泰 49%股权，收购完成后，昊为泰将成为公司的全资 子公司。 独立董事对本议案发表了同意的独立意见。 保荐机构对本议案发表了无异议的《核查意见》。 表决结果：同意 9 票、反对 0 票、弃权 0 票。 证券代码：688426 证券简称：康为世纪 公告编号：2025-038 江苏康为世纪生物科技股份有限公司 第二届董事会第十七次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司(以下简称"公司")第二届董事会第十七次会议 于 2025 年 10 月 13 日上午 10:00 以现场结合通讯形式召开，本次会议通知及相关材料已 于 2025 年 9 月 30 日发出。会议应出席董事 9 人，实际到会董事 9 人，会议由公司董事 长王春香主持。公司全体高级管理人员列席了本次会议。 本次会议的召集、召 ...

| 2025-10-13 | 康为世纪 | 688426 | 28.12 15.91 | 447.39 | 申万宏源证券有限 公司国际部 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 华泰证券股公有限 公司上海分公司 | 卖出营业部 | 10月13日，康为世纪大宗交易成交15.91万股，成交额447.39万元，占当日总成交额的11.38%，成交价28.12元，较市场收盘价28.12元持平。 ...

康为世纪公告，公司计划以1788.5万元的对价收购控股子公司上海昊为泰生物科技有限公司少数股东上 海天昊生物科技有限公司持有的49%股权。收购完成后，昊为泰将成为公司的全资子公司。本次交易构 成关联交易，但不构成重大资产重组。此次交易旨在加强子公司管理，提高经营决策效率，增强公司整 体盈利能力及竞争力。交易已经公司董事会和独立董事审议通过，无需提交股东会批准。 ...

Core Insights - As of October 10, a total of 92 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stocks with the longest streak of net buying are Kangwei Century and Fucheng Co., both of which have seen net buying for 12 consecutive trading days [1] - Other notable stocks with significant net buying days include Shenzhen New Star, Daming City, Darui Electronics, Xiangyuan Cultural Tourism, Changyuan Donggu, Hangzhou Kelin, Hengtong Optic-Electric, and Wujin Stainless Steel [1]

Core Viewpoint - 康为世纪's stock price decreased by 0.82% on October 10, with a trading volume of 47.09 million yuan, indicating a potential market reaction to recent financial performance and investor sentiment [1] Financing Summary - On October 10, 康为世纪 had a financing buy-in amount of 6.84 million yuan, with a net financing purchase of 2.75 million yuan, reflecting strong investor interest [1] - The total financing balance reached 116 million yuan, accounting for 11.05% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of leverage [1] - No short selling activity was recorded on October 10, with a short selling balance of 0 yuan, also reflecting a high percentile position over the past year [1] Financial Performance - For the first half of 2025, 康为世纪 reported a revenue of 87.12 million yuan, representing a year-on-year growth of 29.74%, indicating strong sales performance [2] - The company experienced a net loss attributable to shareholders of 55.91 million yuan, which is a decrease of 11.70% compared to the previous period, highlighting ongoing profitability challenges [2] Shareholder and Dividend Information - Since its A-share listing, 康为世纪 has distributed a total of 48.63 million yuan in dividends [3] - As of June 30, 2025, the number of shareholders increased by 0.25% to 3,949, while the average number of circulating shares per person decreased by 0.25% to 9,621 shares [2][3] - The largest circulating shareholder is 融通健康产业灵活配置混合A/B, holding 3.60 million shares, which decreased by 16,120 shares compared to the previous period [3]

江苏康为世纪生物科技股份有限公司 关于注销部分募集资金专户的公告 公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688426 证券简称：康为世纪 公告编号：2025-037 江苏康为世纪生物科技股份有限公司（以下简称"公司"或"康为世纪"）首次公开发 行股票募集资金按照相关法律、法规和规范性文件的规定在银行开立了募集资金专户。 鉴于公司首次公开发行募集资金投资项目之一的"医疗器械及生物检测试剂产业化项目" 已经结项，近日，公司办理完成了部分募集资金专户的注销手续，相关情况具体如下： 一、募集资金基本情况 2022 年 9 月 1 日，经中国证券监督管理委员会《关于同意江苏康为世纪生物科技股 份有限公司首次公开发行股票注册的批复》（证监许可[2022]2003 号）核准，公司向社 会首次公开发行人民币普通股（A 股）股票 2,329.0278 万股，股票面值为人民币 1 元， 发行价格为每股人民币 48.98 元，此次公开发行股份募集资金总额为人民币 114,075.78 万元，扣除所有股票发行费用人民币 8,645 ...

Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

9月23日，康为世纪盘中下跌2.05%，截至09:38，报26.32元/股，成交234.57万元，换手率0.23%，总市 值29.61亿元。 康为世纪所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基金重仓、融资融券、 小盘、医疗器械、体外诊断等。 截至6月30日，康为世纪股东户数3949.00，较上期增加0.25%；人均流通股9621股，较上期减少0.25%。 2025年1月-6月，康为世纪实现营业收入8711.87万元，同比增长29.74%；归母净利润-5591.11万元，同 比减少11.70%。 分红方面，康为世纪A股上市后累计派现4863.19万元。 机构持仓方面，截止2025年6月30日，康为世纪十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第一大流通股东，持股360.00万股，相比上期减少16.12万股。中欧时代先锋股票A （001938）位居第三大流通股东，持股200.00万股，为新进股东。圆信永丰医药健康A（006274）位居 第七大流通股东，持股67.28万股，相比上期增加9.18万股。圆信永丰聚优A（010469）位居第八大流通 股东，持股66.00万 ...

Market Overview - On September 17, the Shanghai Composite Index rose by 0.37%, with the total margin trading balance reaching 2405.44 billion yuan, an increase of 12.79 billion yuan compared to the previous trading day [1] - The margin trading balance in the Shanghai market was 1221.39 billion yuan, up by 3.96 billion yuan; in the Shenzhen market, it was 1176.13 billion yuan, up by 8.77 billion yuan; and in the Beijing Stock Exchange, it was 7.909 billion yuan, up by 0.065 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 22 sectors saw an increase in margin trading balances, with the non-bank financial sector leading with an increase of 3.102 billion yuan, followed by the power equipment and electronics sectors with increases of 2.528 billion yuan and 1.647 billion yuan, respectively [1] Stock Performance - A total of 1847 stocks experienced an increase in margin trading balances, accounting for 49.62% of the total, with 347 stocks seeing an increase of over 5% [1] - Shanghai Construction Engineering had the largest increase in margin trading balance, reaching 1.137 billion yuan, a rise of 114.15%, with its stock price increasing by 9.97% [1] - Other notable stocks with significant increases in margin trading balances included Kailong High-Tech and Feng'an Co., with increases of 77.63% and 63.40%, respectively [1] Top Gainers - The top 20 stocks with the highest increase in margin trading balances averaged an increase of 8.40%, with peak gains from Feng'an Technology, Zhejiang Hengwei, and Online and Offline, which rose by 20.00%, 19.99%, and 18.98%, respectively [2][3] Top Decliners - Conversely, 1875 stocks saw a decrease in margin trading balances, with 247 stocks experiencing a decline of over 5% [4] - Tianming Technology had the largest decrease, with a margin trading balance of 6.5227 million yuan, down by 50.73% [5] - Other significant decliners included Henghe Co. and Tianji Co., with decreases of 38.37% and 29.81%, respectively [5]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical and biotechnology industry [6] Core Viewpoints - The pharmaceutical sector has outperformed the CSI 300 index, with the Shenwan Pharmaceutical Biotechnology Index rising by 2.46% from September 1 to September 14, 2025, and by 26.80% year-to-date, surpassing the CSI 300 index by 1.16 percentage points and 11.88 percentage points respectively [1][13] - The current valuation of the pharmaceutical sector stands at 31.58 times (TTM overall method, excluding negative values), with a premium of 148.92% compared to the CSI 300 index [16] - The National Medical Products Administration (NMPA) has announced measures to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [20] - The ongoing reforms in drug review and approval systems are expected to enhance the efficiency of clinical trials and accelerate the development of innovative drugs, benefiting companies in this sector [21] Summary by Sections 1. Biweekly Market Review - The pharmaceutical sector's performance from September 1 to September 14, 2025, shows a 2.46% increase, ranking 8th among 31 Shenwan first-level industry indices [11] - Year-to-date, the pharmaceutical sector has increased by 26.80%, also ranking 8th among the indices [13] - The top ten stocks by increase include Zhendemedical (+46.67%), Haooubo (+34.22%), and Kangwei Century (+30.28%), while the top ten stocks by decrease include Shutaishen (-24.15%) and Shanghai Yizhong (-15.39%) [17][18] 2. Important Events - On September 12, 2025, the NMPA released an announcement to support innovative drug development by optimizing the clinical trial review process [20] 3. Industry Insights - The report emphasizes the acceleration of innovative drug development in China, with significant results emerging and ongoing policy optimizations expected to further support this trend [21] - The second half of 2025 is expected to see continued focus on innovative drugs, international expansion, and the clearing of procurement processes, with specific attention to insulin and orthopedic sectors [21]